Q-omics provides the consensus-scored YBX3 profile across patient tissues and cancer cell-line models. YBX3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, YBX3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, YBX3 protein abundance shows 23,153 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where YBX3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YBX3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YBX3 survival associations across molecular data types. YBX3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YBX3 RNA expression–survival associations across cancer types. High YBX3 expression shows unfavorable associations in ACC, LGG, KIRP, PAAD and KIRC, but favorable associations in LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for YBX3 RNA expression.
This table summarizes YBX3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for YBX3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YBX3 shows lower tumor expression in BRCA and UCEC and higher tumor expression in KIRC, KIRP, COAD and THCA. The KIRC box plot shows higher YBX3 RNA expression in tumor versus normal tissue (log2 FC = +1.645, t-test p < 0.001).
This table shows molecular features associated with YBX3 in patient tissues and cancer cell lines. In patient samples, YBX3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, YBX3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
